2020 Event Partners
Diagnostic certainty for every patient is a critical first step in the fight against cancer. Agilent’s Dako pathology solutions are designed to help hospitals and pathology laboratories around the world make fast and accurate diagnoses. This enables the most effective treatment decisions for cancer patients, ultimately improving patient care and enhancing survival rates.
Our unique perspectives, built from decades of scientific expertise and precision delivery of the largest volume of drug development data in the world, helps our clients identify new approaches and anticipate tomorrow’s challenges as they evolve. Driven by a passion for excellence and a relentless commitment to quality, we unlock opportunities that advance innovation and deliver on the promise of a healthier world.
Diaceutics is the diagnostic development and commercialization service provider. We have been leading this field for 13 years, entirely focused on the intersection between diagnostics and therapeutic decision making. We provide an end to end service that encompasses everything from understanding the diagnostic landscape to test implementation in treatment pathways. This is all enabled by a robust flow of data from our global laboratory network. Our ultimate goal is to drive better testing to enable better treatment decisions for patients.
Guardant Health is a pioneer in non-invasive cancer diagnostics, addressing challenges across the cancer care continuum. The company has raised more than $200 million from leading venture capital firms and in 2014 launched Guardant360, the first comprehensive liquid biopsy for clinical use. Guardant Health is improving therapy selection for advanced cancer patients across the globe using its proprietary cell-free circulating tumor DNA NGS platform. Guardant Health is partnered with biopharmaceutical companies to prospectively screen patients for trial enrollment, develop companion diagnostics to support clinical adoption, and use retrospective analysis for early insights into patient response and tumor evolution, as well as accelerate the development of new therapies.
As an expert in immune biomarkers, HalioDx goal is to play a leading role in partnering with academic and pharmaceutical industry to leverage the immune contexture concept and deliver practical routine diagnostic tools to significantly impact therapy prescription for the benefit of patients. By precisely measuring the immune reaction in and around the tumor, HalioDx first tests already allow clinicians to determine the degree of severity of a patient’s disease and predict the response to treatment, regardless of the cancer stage or the molecular class..
NeoGenomics is a premier cancer diagnostics and pharma services company serving oncologists, pathologists, pharmaceutical companies, academic centers, and others with innovative diagnostic, prognostic and predictive testing. Our vision embodies uncompromising quality, exceptional service, and innovative solutions. We have a network of CAP-accredited, CLIA-licensed facilities across the U.S., but work hard to maintain easy access and all the efficiencies of a smaller operation.
Q2 Solutions is a leading global clinical trials laboratory services organization that partners with biopharmaceutical, medical device and diagnostics customers to transform science and data into actionable medical insights. Its laboratory services span the development lifecycle from Discovery through Clinical Trials to Commercialization that includes predictive biomarker solutions for Companion Diagnostics.
Thermo Fisher Scientific is the world leader in serving science. Our mission is to enable our customers to make the world healthier, cleaner and safer. We support precision medicine from translational research to the development of companion diagnostics with innovative technologies and service through our Thermo Scientific, Applied Biosystems, Invitrogen, Gibco and Ion Torrent brands.
Accelerate your next breakthrough in diagnostics and therapeutics. Abcam’s comprehensive portfolio of high quality, customizable solutions are ideal for diagnostic and therapeutic applications. Our technical ability coupled with a flexible commercial approach enables us to deliver projects that will help achieve your goals
Almac Diagnostics is a stratified medicine company specialising in biomarker driven clinical trials. Our diagnostic experience spans oncology, immunology, CNS and infective diseases. Our global laboratories, based in the UK and US offer tailored solutions from discovery to commercialisation: Biomarker discovery. Custom assay development & validation. DNA and RNA panel solutions. Flexible CDx development & commercialisation. Expert regulatory support. Bioinformatics & software development. Your Clinical Trial Diagnostic Partner.
Biocartis aims to provide direct access to personalized medicine for patients worldwide by developing fully integrated and broadly applicable molecular diagnostics. Our platforms can be used in a wide variety of healthcare settings to enable rapid and high-quality care close to patients.
Biodesix® is an experienced partner in the field of blood-based molecular diagnostic testing. Our comprehensive diagnostic testing capabilities help our partners decipher the complexity of cancer by interpreting genomic and proteomic information from both tumor biology and the patient’s immune response. Biodesix enables our partners throughout the discovery, development and commercialization of personalized diagnostics to support new therapies with companion diagnostic strategiess.
Boston Healthcare is a global consulting firm focused on enabling companies to derive optimal value from innovative products and services that have the potential to transform standards of care and significantly improve health outcomes. We have aligned our services and expertise to assure that the innovators reshaping healthcare are rewarded for their efforts and commitment, and we tailor our approach to the product and specific characteristics of each geographic market.
• Epic Sciences’ circulating tumor cell (CTC) platform can assist in stratifying patient populations in either observational or interventional studies with an emphasis on prostate and breast cancer.
• Our platform has the ability to conduct multi-parametric single cell analysis of protein expression, cell morphology and single cell genomics to see the widest biological range of cells with unmatched sensitivity.
• Epic Sciences works with investigators at cancer centers and pharmaceutical companies to bring functional cell profiling techniques to pair rare cell types, both genotypically and phenotypically, with outcomes.
Leica Biosystems is a global leader in workflow solutions and automation, integrating each step in the workflow. As the only company to own the workflow from biopsy to diagnosis, we are uniquely positioned to break down the barriers between each of these steps. Our mission of “Advancing Cancer Diagnostics, Improving Lives” is at the heart of our corporate culture. Our easy-to-use and consistently reliable offerings help improve workflow efficiency and diagnostic confidence. In line with our Mission, we have established the following challenge for ourselves: Enable patients to get their diagnosis within 24 hours from biopsy. This is a goal we are striving towards, a goal that will guide our future strategies. This vision aims to decrease the time it takes from biopsy to patient diagnosis, to a 24 hour period. With a presence in every step of the workflow, no other company is positioned to streamline all these steps so that the whole process takes less than 24 hours.
PathAI is a leading provider of AI-powered research tools and services for pathology. PathAI’s platform promises substantial improvements to the accuracy of diagnosis and the efficacy of treatment of diseases like cancer, leveraging modern approaches in machine and deep learning. Based in Boston, PathAI works with leading life sciences companies and researchers to advance precision medicine.
Ultivue is a venture-backed company developing reagent-driven solutions for high-performance biological imaging in situ, combining unlimited multiplexing at high speed with high spatial resolution. Ultivue’s proprietary solutions will enable researchers to realize the promise of personalized medicine. The company has launched products and services that will seamlessly integrate into existing workflows for biomarker discovery, assay validation, and companion diagnostic applications.
Unilabs is a leader in Companion Diagnostic testing in Europe with several years of experience with the associated necessary global, customized logistics & regulatory know-how. Unilabs is Serving Pharma as a highly customer centric and specialized bioanalytical laboratory service partner with structured processes to reduce budget risks & stalling of drug development.Unilabs has more than 8.000 employees, and more than 30 years of clinical trials experience, handling more than 3.000 studies involving a broad range of matrices from numerous species and in a vast number of therapeutic areas.
Spotlight, Panel, Meeting Partners & Exhibitors
Cofactor Genomics, Inc. is a translational and clinical assay company using RNA as the foundation for providing a better understanding of disease. We’ve invested in the development of proprietary databases focused on (1) cancer-specific gene expression and (2) unique immune cell RNA expression fingerprints. These databases enable us to quantify complex molecular profiles, and provide comprehensive characterization of immune response in all solid tumor tissues. Cofactor leverages our expertise in high-throughput sequencing, CAP-accredited laboratory, and unique machine-learning algorithms to deliver candidate biomarkers in an easy-to-interpret report.
Flagship Biosciences helps drug developers confidently define their path to success. Our Computational Tissue Analysis (cTA™) platform provides the quantitative, contextual tissue interpretation necessary to make timely decisions.
With a unique combination of our technology platform, extensive expertise across multiple disciplines (e.g., pathology, biology, image analysis, software engineering), and an in-house CLIA lab, Flagship Biosciences develops quantitative tissue biomarker interpretations for clinical development of tissue-based diagnostics, including companion diagnostics (CDx). We collaborate with biopharmaceutical teams at every stage of the clinical trial to:
- Make informed pipeline decisions that will accelerate the right clinical path
- Enable critical go/no go decisions based on confirmation of action
- Design, implement and evaluate prototype diagnostic strategies
- Differentiate commercial strategies to increase probability of success
Over 100 pharmaceutical, biotech, and medical device firms rely on Flagship’s technology for success. As the largest clinical tissue-image-analysis operation in the US, Flagship has completed over 400 projects since 2009.
Genomenon provides immediate insight into the published genomic research for every disease, gene, and mutation found in the scientific literature. Pharmaceutical and biotech companies license Genomenon’s comprehensive genomic landscape on any given disease to identify and prioritize genomic biomarkers for drug discovery and clinical trial targets
Randox Biosciences are a highly innovative global leader in clinical diagnostic manufacturing supplying the world’s top CRO’s and biopharmaceutical companies. We have technical expertise in diagnostic and CDx assay development utilising single analyte assays, as well as multiplex assays that test up to 23 biomarkers using one patient sample via our Evidence range of analysers. This utilises our proprietary Biochip Array Technology which was developed using our in house range of antibodies, proteins and conjugates. We also offer a custom development service for all our raw materials for the biopharmaceutical and diagnostic industries. As well as custom assay development, our custom services also include polyclonal and monoclonal development and recombinant antibody fragments (sdAb, scFv, Fab).